Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Annals of Clinical and Experimental Neurology · 30.06.2026 · 20 (2) · 26-35
DOI: 10.17816/acen.1512 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Experimental Neurology, online erschienen am 30.06.2026. Verfasst von Alexey N. Boyko und 26 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD.
Aim
The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters.
Results
The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported.
Conclusion
The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
Zitieren
APA
Boyko, A. N., Zakharova, M. N., Simaniv, T. O., Goncharova, Z. A., Spirin, N. N., Totolyan, N. A., Bakhtiyarova, K. Z., Greshnova, I. V., Dudin, V. A., Korobko, D. S., Kotov, S. V., Parshina, E. V., Poverennova, I. E., Lebedev, V. M., Smagina, I. V., Khairutdinova, D. F., Trushnikova, T. N., Zaslavsky, L. G., Khabirov, F. A., …, & Porozova, A. A. (2026). Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial. Annals of Clinical and Experimental Neurology, 20(2), 26-35. https://doi.org/10.17816/acen.1512
Vancouver
Boyko AN, Zakharova MN, Simaniv TO, Goncharova ZA, Spirin NN, Totolyan NA, et al. Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial. Annals of Clinical and Experimental Neurology. 2026;20(2):26-35. doi:10.17816/acen.1512
BibTeX
@article{Boyko2026,
author = {Boyko, Alexey N. and Zakharova, Mariya N. and Simaniv, Taras O. and Goncharova, Zoya A. and Spirin, Nikolay N. and Totolyan, Natalia A. and Bakhtiyarova, Klara Z. and Greshnova, Irina V. and Dudin, Vyacheslav A. and Korobko, Denis S. and Kotov, Sergey V. and Parshina, Elena V. and Poverennova, Irina E. and Lebedev, Valeriy M. and Smagina, Inna V. and Khairutdinova, Diana F. and Trushnikova, Tatiana N. and Zaslavsky, Leonid G. and Khabirov, Farit A. and Sivertseva, Stella A. and Tolkacheva, Daria G. and Sapozhnikov, Kirill V. and Gorbunova, Alexandra A. and Krasnova, Marina V. and Linkova, Yulia N. and Zinkina, Arina V. and Porozova, Anastasiya A.},
title = {Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial},
journal = {Annals of Clinical and Experimental Neurology},
year = {2026},
volume = {20},
number = {2},
pages = {26--35},
doi = {10.17816/acen.1512}
}
EUVIMED